This study is in progress, not accepting new patients
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
Summary
- Eligibility
- for people ages 18-130 (full criteria)
- Location
- at Los Angeles, California and other locations
- Dates
- study startedcompletion around
- Principal Investigator
- by Kelly E. McCann, MD, PhD

Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientist at UCLA
- Kelly E. McCann, MD, PhD
HS Assistant Clinical Professor, Medicine. Authored (or co-authored) 19 research publications
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- AstraZeneca
- Links
- Breast Cancer Study Locator details (for US) Sign up for this study
- ID
- NCT05629585
- Phase
- Phase 3 Breast Cancer Research Study
- Study Type
- Interventional
- Participants
- About 1168 people participating
- Last Updated